Real-time enrollment status for this based on the limited information provided, this appears to be an extension study for secukinumab, but the primary medical condition is not clearly stated in the given data. secukinumab is commonly used to treat: psoriasis clinical trial
Current Status
Recruiting
Checked: March 2, 2026 at 7:19 AM UTC
| NCT Number | NCT04638647 |
| Recruiting Status | Recruiting |
| Condition | Based on the limited information provided, this appears to be an extension study for secukinumab, but the primary medical condition is not clearly stated in the given data. Secukinumab is commonly used to treat: Psoriasis |
| Phase | Clinical Trial |
| Target Enrollment | 715 participants |
| Active Locations | 28 sites in the US |
| Sponsor | Novartis Pharmaceuticals |
| Last Updated on CT.gov | December 22, 2025 (Dec 22, 2025) |
As of March 2, 2026: Clinical trial NCT04638647 is currently recruiting participants. This clinical trial study for based on the limited information provided, this appears to be an extension study for secukinumab, but the primary medical condition is not clearly stated in the given data. secukinumab is commonly used to treat: psoriasis is actively seeking new participants at 28 locations across the United States. The study is sponsored by Novartis Pharmaceuticals. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT04638647 is actively recruiting participants as of March 2, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 28 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT04638647 was last updated Dec 22, 2025 (December 22, 2025). HelloStudys verifies this status automatically.